低 T3 综合征是继发性噬血细胞性淋巴组织细胞增多症不良预后的预测指标。
Low T3 syndrome is a prognostic marker of poor outcomes in secondary hemophagocytic lymphohistiocytosis.
机构信息
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
出版信息
Leuk Lymphoma. 2020 Dec;61(12):2947-2954. doi: 10.1080/10428194.2020.1789623. Epub 2020 Jul 9.
This study aimed to examine the association between low T3 syndrome and overall survival (OS) in patients with secondary hemophagocytic lymphohistiocytosis (sHLH). The study consisted of 111 consecutive patients hospitalized due to newly diagnosed sHLH with detailed thyroid hormone profiles on admission. Low T3 syndrome was found in 75.7% of the studied sHLH population. After a median follow-up of 83 (interquartile range 25-365) days, there were 60 (71.4%) cumulative deaths in the low T3 syndrome group and 13 (48.1%) in the euthyroid group. Survival analysis showed a lower survival probability for patients with low FT3 than for those with normal FT3 (median OS, 60 vs. 365 days, = .011). In the multivariate analysis, low T3 syndrome was an independent prognostic factor for OS (HR = 2.474; 95% CI 1.351-4.532, = .003). Low T3 syndrome is frequently found and associated with worse outcomes in patients with sHLH.
本研究旨在探讨继发性噬血细胞性淋巴组织细胞增生症（sHLH）患者低三碘甲状腺原氨酸（T3）综合征与总生存期（OS）的关系。该研究纳入了 111 例因新诊断 sHLH 住院的连续患者，这些患者在入院时进行了详细的甲状腺激素谱检测。研究人群中 75.7%的患者存在低 T3 综合征。中位随访 83 天（四分位距 25-365 天）后，低 T3 综合征组有 60 例（71.4%）累积死亡，而甲状腺功能正常组有 13 例（48.1%）。生存分析显示，低 FT3 患者的生存率低于 FT3 正常患者（中位 OS，60 天 vs. 365 天， = .011）。多变量分析显示，低 T3 综合征是 OS 的独立预后因素（HR = 2.474；95%CI 1.351-4.532， = .003）。低 T3 综合征在 sHLH 患者中较为常见，并与不良结局相关。
Zotero 插件